Telmisartan delays myocardial fibrosis in rats with hypertensive left ventricular hypertrophy by TGF-β1/Smad signal pathway

Hypertension Research

Volumn 37, Issue 1, 2014, Pages 43-49

  Zhang, Yong ^a   Shao, Liang ^a   Ma, Aiqun ^a   Guan, Gongchang ^a   Wang, Junkui ^a   Wang, Yaping ^a   Tian, Gang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

hypertensive myocardial remodeling; myocardial fibrosis; telmisartan; TGF 1 Smad

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; COLLAGEN FIBER; MATRIX METALLOPROTEINASE; SMAD PROTEIN; TELMISARTAN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEMODYNAMIC MONITORING; HYPERTENSION; IMMUNOASSAY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOTTING, WESTERN; COLLAGEN; ECHOCARDIOGRAPHY; FIBROSIS; HEMODYNAMICS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84891807068     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.119     Document Type: Article

References (26)

1. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Kjeldsen SE, Hildebrandt P, Dige-Petersen H, Rokkedal J, Ibsen H. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. J Hum Hypertens 2005; 19: 301-307. (Pubitemid 40514907)
2. López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48: 89-96. (Pubitemid 43929208)
3. Chen YG, Meng AM. Negative regulation of TGF-beta signaling in development. Cell Res 2004; 14: 441-449. (Pubitemid 43231788)
4. Massague J, Gomis RR. The logic of TGF beta signaling. FEBS Lett 2006; 580: 2811-2820.
5. Zhu XY, Daghini E, Rodriguez-Porcel M, Chade AR, Napoli C, Lerman A, Lerman LO. Redox-sensitive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia. Atherosclerosis 2007; 193: 62-69. (Pubitemid 46776711)
6. Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol 2009; 131: 471-481.
7. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, Klövekorn WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart-structural deterioration and compensatory mechanisms. Circulation 2003; 107: 984-991. (Pubitemid 36258721)
8. Briest W, Homagk L, Rassler B, Ziegelhö ffer-Mihalovicová B, Meier H, Tannapfel A, Leiblein S, Saalbach A, Deten A. Zimmer HG. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004; 44: 410-418. (Pubitemid 39281488)
9. Stawowy P, Margeta C, Kallisch H, Seidah NG, Chrétien M, Fleck E, Graf K. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta 1 involves furin-convertase. Cardiovasc Res 2004; 63: 87-97. (Pubitemid 38759813)
10. Mü ller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007; 25: 1958-1966. (Pubitemid 47356638)
11. Ciulla MM, Paliotti R, Esposito A, D?̀ez J, López B, Dahlöf B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis-results of a randomized trial. Circulation 2004; 110: 552-557. (Pubitemid 39031172)
12. Kawasaki D, Kosugi K, Waki H, Yamamoto K, Tsujino T, Masuyama T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007; 71: 524-529. (Pubitemid 46513459)
13. Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005; 69: 1244-1248. (Pubitemid 41382947)
14. Cuspidi C, Sala C, Zanchetti A. Management of hypertension in patients with left ventricular hypertroph. Curr Hypertens Rep 2007; 9: 498-505.
15. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Study. Circulation 2009; 119: 2471-2479.
16. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 2008; 317: 43-50.
17. Yuan WH, Varga J. Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 2001; 276: 38502-38510.
18. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, Novak L, Renfrow MB, Chen YF. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 2008; 102: 185-192. (Pubitemid 351651122)
19. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005; 46: 1347-1354. (Pubitemid 43189734)
20. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003; 21: 1627-1630. (Pubitemid 37076343)
21. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
22. Leppäranta O, Myllärniemi M, Salmenkivi K, Kinnula VL, Keski-Oja J, Koli K. Reduced phosphorylation of the TGF-Beta signal transducer Smad2 in emphysematous human lung. COPD 2009; 6: 234-241.
23. Dasgupta C, Zhang L. Angiotensin II receptors and drug discovery in cardiovascular disease. Drug Discov Today 2011; 16: 22-34.
24. Tziakas DN, Chalikias GK, Stakos DA, Papazoglou D, Papanas N, Papatheodorou K, Chatzikyriakou SV, Kotsiou S, Maltezos E, Boudoulas H. Effect of angiotensin converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opin Pharmacother 2007; 8: 2225-2234. (Pubitemid 350001586)
25. Okada M, Kosaka N, Hoshino Y, Yamawaki H, Hara Y. Effects of captopril and telmisartan on matrix metalloproteinase-2 and-9 expressions and development of left ventricular fibrosis induced by isoprenaline in rats. Biol Pharm Bull 2010; 33: 1517-1521.
26. Liang B, Leenen FH. Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. J Cardiovasc Pharmacol 2008; 51: 457-466.